IntroductionPatients with adverse pathological features (APF) at radical prostatectomy (RP) for prostate cancer (PC) are candidates for adjuvant treatment. Clinicians lack reliable markers to predict these APF preoperatively. Protein tyrosine phosphatase 1B (PTP-1B) is involved in migration and invasion of PC, and its expression could predict presence of APF. Our aim was to compare PTP-1B expression in patients with and without APF, and to explore PTP-1B expression as an independent prognostic factor.MethodsTissue microarrays (TMAs) were constructed using RP archival specimens for immunohistochemical staining of PTP-1B; expression was reported with a standardized score (0-9). We compared median PTP-1B score between cases with and without APF. We constructed two logistic regression models, one to identify the independence of PTP-1B score from biologically associated variables (metformin use and type 2 diabetes mellitus [T2DM]) and the second to seek independence of known risk factors (Gleason score and prostate specific antigen [PSA]).ResultsA total of 73 specimens were suitable for TMA construction. Forty-four (60%) patients had APF. The median PTP-1B score was higher in those with APF: 8 (5-9) vs 5 (3-8) (p=0.026). In the logistic regression model including T2DM and metformin use, the PTP-1B score maintained statistical significance (OR 1.21, 95% CI 1.01-1.45, p=0.037). In the model including PSA and Gleason score; the PTP-1B score showed no independence (OR 1.68, 95% CI 0.97-1.41, p=0.11). The area under the curve to predict APF for the PTP-1B score was 0.65 (95% CI 0.52-0.78, p=0.03), for PSA+Gleason 0.71 (95% CI 0.59-0.82, p=0.03), and for PSA+Gleason+PTP-1B score 0.73 (95% CI 0.61-0.84, p=0.001).DiscussionPatients with APF after RP have a higher expression of PTP-1B than those without APF, even after adjusting for T2DM and metformin exposure. PTP-1B has a good accuracy for predicting APF but does not add to known prognostic factors.

中文翻译：

---

有和无不良病理特征的局限性前列腺癌患者磷酸酶 PTP-1B 表达的差异

简介在前列腺癌 (PC) 根治性前列腺切除术 (RP) 中出现不良病理特征 (APF) 的患者是辅助治疗的候选者。临床医生缺乏可靠的标志物来术前预测这些 APF。蛋白酪氨酸磷酸酶1B（PTP-1B）参与PC的迁移和侵袭，其表达可以预测APF的存在。我们的目的是比较患有和不患有APF的患者中PTP-1B的表达，并探讨PTP-1B表达作为独立的预后因素。方法使用RP档案标本构建组织微阵列（TMA），用于PTP-1B的免疫组织化学染色；表达以标准化评分（​​0-9）报告。我们比较了有 APF 和无 APF 病例之间的中位 PTP-1B 评分。我们构建了两个逻辑回归模型，第一个模型是为了确定 PTP-1B 评分与生物学相关变量（二甲双胍使用和 2 型糖尿病 [T2DM]）的独立性，第二个模型是为了寻求已知风险因素（格里森评分和前列腺特异性抗原）的独立性[PSA]）。结果共有73个试件适合TMA施工。四十四 (60%) 名患者患有 APF。患有 APF 的患者的中位 PTP-1B 评分较高：8 (5-9) vs 5 (3-8) (p=0.026)。在包含 T2DM 和二甲双胍使用的逻辑回归模型中，PTP-1B 评分保持统计学显着性（OR 1.21，95% CI 1.01-1.45，p=0.037）。模型中包括PSA和Gleason评分； PTP-1B 评分显示不具有独立性（OR 1.68，95% CI 0.97-1.41，p=0.11）。 PTP-1B 评分预测 APF 的曲线下面积为 0.65（95% CI 0.52-0.78，p=0.03），PSA+Gleason 为 0.71（95% CI 0.59-0.82，p=0.03），PSA +Gleason+PTP-1B 评分 0.73（95% CI 0.61-0.84，p=0.001）。 讨论 RP 后出现 APF 的患者比无 APF 的患者具有更高的 PTP-1B 表达，即使在调整 T2DM 和二甲双胍暴露后也是如此。 PTP-1B 对于预测 APF 具有良好的准确性，但不会增加已知的预后因素。